S. Al-Batran

Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

Mathias Rummel, S. Al-Batran, Soo-Z. Kim et al. · Journal of Clinical Oncology · 2005 · 440 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

Uğur Şahin, Ö. Türeci, Georgy M. Manikhas et al. · Annals of Oncology · 2021 · 359 citations · Full text

Medicine, Oncology, Pharmacology +14

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

S. Al-Batran, J. T. Hartmann, Ralf‐Dieter Hofheinz et al. · Annals of Oncology · 2008 · 281 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Markus Moehler, Annett Maderer, Peter Thuss‐Patience et al. · Annals of Oncology · 2020 · 113 citations

Medicine, Oncology, Pharmacology +17

Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells

Robert Dengler, Ursula Muunstermann, S. Al-Batran et al. · British Journal of Haematology · 1995 · 102 citations

Medicine, Hematology, Pathology +17